19:19 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest depleting microglia or inhibiting their inflammatory activity could help treat obesity. In a mouse model of obesity, depletion of microglia in the mediobasal hypothalamus with the CSF1R inhibitor PLX5622 or knockout...
07:00 , Oct 6, 2016 |  BC Innovations  |  Targets & Mechanisms

Seeking cysteines

In settling the question of how Biogen Inc.'s Tecfidera dimethyl fumarate (DMF) acts in multiple sclerosis, a Scripps team has identified PKCθ as a key driver, sitting atop an NF-κB pathway to immunosuppression. The results...
07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Inhibitor of κ light gene enhancer in B cells kinase α (IKKα; IKBKA; IKK1; CHUK; NFKBIKA); IKKβ (IKBKB; IKK2; NRKBIKB)

Cancer INDICATION: Cancer In vitro and mouse studies suggest the natural product (+)-ainsliadimer A could help treat cancer. In vitro, (+)-ainsliadimer A covalently bound the cysteine 46 residue of IKKα and IKKβ (Ki = 30 nM) and...
07:00 , Mar 12, 2015 |  BC Innovations  |  Targets & Mechanisms

TBK1 and beyond

Biogen Idec Inc.'s partnership with Columbia University and the HudsonAlpha Institute for Biotechnology has yielded a new target in ALS - TBK1 - that provides a link between autophagy, neuroinflammation and the pathology of the...
07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Inhibitor of k-light polypeptide gene enhancer in B cells kinase-b (IKBKB; IKK2); b-amyloid (Ab) ...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; obesity Inhibitor of k-light polypeptide gene enhancer in B cells kinase-b (IKBKB; IKK2) Mouse studies suggest...
08:00 , Feb 3, 2014 |  BioCentury  |  Emerging Company Profile

ImStar: Neuronal pacifier

ImStar Therapeutics Inc. is using new discoveries about the physiopathology of amyotrophic lateral sclerosis to develop small molecules that block a key kinase interaction leading to immune-related neuroinflammation. The company hopes to have preclinical proof-of-concept...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

This week in techniques Approach Summary Licensing status Publication and contact information Assays & screens Virus-based in vivo RNAi screens to identify host interactions In vitro and...
07:00 , Sep 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115); inhibitor of k light polypeptide gene enhancer in B cells...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Inhibitor of k light polypeptide gene enhancer in B cells kinase-b...